Nonrelapse Mortality, Safety, and Long-Term Trajectory After GVHD Control

Rawan Faramand, MD, says the finding that stands out most from newer approaches is the nonrelapse mortality of about 3% reported in the Precision-T trial, which compares favorably with historical rates of 15% to 20%, particularly in the myeloablative setting. Infection is her other focus, because it is a major complication of post-transplant cyclophosphamide and because allogeneic transplant is increasingly used to consolidate patients after chimeric antigen receptor T-cell therapy, who have ongoing B-cell aplasia and hypogammaglobulinemia. Strategies that reduce infection risk, preserve immune reconstitution, and deliver very low nonrelapse mortality are therefore intriguing to her, but she stresses that longer follow-up from Precision-T is needed to confirm that low nonrelapse mortality and less moderate to severe chronic graft-vs-host disease (GVHD) do not come at the cost of higher relapse. She also emphasizes patient-reported outcomes, which improved across multiple domains in Precision-T, and wants to know whether patients are back at work, at school, and functioning well at 2 and 3 years, not just at 1 year. Turning to what reduced GVHD burden means downstream, Caspian Oliai, MD, MS, argues that preventing GVHD through the prophylaxis regimen is the best strategy because it avoids high-dose steroids for severe acute or later chronic GVHD, lowers total immunosuppression, and preserves the integrity of the graft-vs-leukemia effect as it matures. In his own practice, a patient asking to return to work at 3 or 6 months is a general but important gauge of how well the strategy worked. Dr Faramand agrees, noting that chronic GVHD is difficult to manage, that most affected patients require lifelong immunosuppression with added infections and bone health problems, and that reducing GVHD from the outset is the ultimate goal because chronic GVHD fundamentally alters survivorship.